You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 58 No. 4, April 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Abstract
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (100)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurogenetics
 •Genetic Disorders
 •Genetics, Other
 •Hypertension
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cerebrovascular and Brain Morphologic Correlates of Mild Cognitive Impairment in the National Heart, Lung, and Blood Institute Twin Study

Charles DeCarli, MD; Bruce L. Miller, MD; Gary E. Swan, PhD; Terry Reed, PhD; Philip A. Wolf, MD; Dorit Carmelli, PhD

Arch Neurol. 2001;58:643-647.

ABSTRACT

Objective  To evaluate the relative risk (RR) of mild cognitive impairment (MCI) associated with cerebrovascular risk factors and cerebrovascular-related brain changes.

Design  Mild cognitive impairment was determined for the subjects of the prospective National Heart, Lung, and Blood Institute Twin Study. Quantitative measures of brain, white matter hyperintensity, cerebral infarction, apolipoprotein E genotype, and psychometric testing were obtained.

Results  Subjects with MCI were older (73.5 ± 3.0 vs 72.1 ± 2.8 years), consumed less alcohol (3.7 ± 5.8 vs 7.0 ± 10.7 drinks per week), had greater white matter hyperintensity volumes (0.56% ± 0.82% vs 0.25% ± 0.34% of cranial volume), and had an increased prevalance of apolipoprotein E4 genotype (31.4% vs 19.2%) than normal subjects. White matter hyperintensity and the presence of the apolipoprotein E4 genotype were associated with a significantly increased risk for MCI. When all subjects were included in the analysis, alcohol consumption was associated with a reduced risk for MCI (RR = 0.93, P<.05). When subjects with a history of symptomatic cerebrovascular disease were excluded from the analysis, elevated midlife diastolic blood pressure was associated with an increased risk for MCI (RR = 1.70, P<.05).

Conclusions  Elevated midlife blood pressures, and the resulting increased white matter hyperintensities, increase the risk for MCI in a group of community-dwelling older men to at least the same degree as apolipoprotein E4 genotype. Given the common occurrence of elevations in midlife blood pressure, early and effective treatment may be warranted to prevent late-life brain abnormalities and MCI. Moreover, since many individuals with MCI progress to clinical dementia, longitudinal evaluations of this cohort will be important.



INTRODUCTION
 Jump to Section
 •Top
 •Introduction
 •Subjects and methods
 •Results
 •Comment
 •Author information
 •References

SEVERAL longitudinal studies show an association between middle-age elevations in blood pressure (BP) and impaired later-life cognition.1, 2, 3, 4, 5 The mechanisms underlying these long-term associations are unclear, but several processes, including disturbed cerebral perfusion or reduced metabolism,6, 7, 8 abnormalities of cerebral white matter,9 and cerebral atrophy,10 have been implicated.

Elevated BP, especially elevated systolic BP and hypertension, are associated with an increased prevalence and extent of white matter hyperintensity (WMHI)9, 11, 12, 13, 14, 15 as well as cerebral atrophy.9, 10, 14, 15, 16 Although the impact of WMHI on memory impairment in the elderly remains uncertain,17 considerable evidence suggests that large volumes of WMHI are associated with other impairments in cognitive performance.9, 13, 15, 18, 19, 20, 21 The extent of brain atrophy and WMHI that accompany middle-life elevations of systolic BP also correlate with the rate of cognitive decline during 10 years.15 While these results support the notion that brain injury in response to long-standing BP elevation can result in mild impairment in various cognitive domains, the clinical significance of these effects remains unclear.

Mild cognitive impairment (MCI) has become increasingly recognized as common in later life.22 Usually defined as isolated memory impairment in an otherwise healthy individual,22 MCI is associated with a yearly risk for Alzheimer disease (AD) that varies from 1% to 25% per year.23 Given that cerebrovascular risk factors, such as hypertension, are often associated with late-life brain abnormalities and cognitive impairment, we sought to examine the relationship between cerebrovascular risk factors, brain morphologic characteristics, and MCI in a group of 369 nondemented, community-dwelling older men who participated in the National Heart, Lung, and Blood Institute (NHLBI) Twin Study.


SUBJECTS AND METHODS
 Jump to Section
 •Top
 •Introduction
 •Subjects and methods
 •Results
 •Comment
 •Author information
 •References

STUDY POPULATION

The NHLBI Twin Study is a longitudinal study of cardiovascular disease and associated cardiovascular disease risk factors in 514 pairs of male twins born between 1917 and 1927, who were 42 to 56 years old when first examined in 1969 to 1972.24, 25 Three follow-up examinations after 10, 16, and 25 years assessed cardiovascular disease status and collected repeated measurements of physiological, biochemical, and psychosocial risk factors.26 In the most recent follow-up examination (1995-1997), brain magnetic resonance (MR) imaging was added to the sequence of tests previously given to these subjects. Analyses in the present study were limited to a subset of 369 individual twins who participated in the fourth examination of this cohort and for whom MR volumetric data and neuropsychological testing were available.

BP DETERMINATION AND DEFINITIONS OF CARDIOVASCULAR DISEASE AND RISK FACTORS

Complete details regarding BP assessment and determination of cerebrovascular risk factors are available elsewhere.14, 15 In brief, however, sitting BP was measured at each examination by 2 independent examiners. Diastolic BP was recorded as the fifth phase. The slope of BP change was determined by linear regression of each individual across the 4 measurements, as described by DeCarli et al.14

Cardiovascular disease and risk factors were determined through medical interviews and physical examination. Subjects' self-report of cardiovascular events and medical procedures were confirmed with medical and hospital records. The final diagnoses of clinical stroke, transient ischemic attack, myocardial infarction, coronary insufficiency, and angina pectoris were determined by trained medical staff who reviewed the medical records and physical examination data and uniformly coded these according to standard protocols. Prevalent coronary heart disease was ascertained on the basis of the surveillance data and electrocardiographic data. Data on medication use were collected at each examination by presentation of medication vials. The ankle-brachial BP ratio, in combination with patient medical and hospital records, was used as a measure of prevalent peripheral vascular atherosclerosis. All subjects were free of cardiovascular disease at the first examination.

Alcohol consumption and smoking behavior were assessed at each examination.14 Alcohol consumption was defined as number of drinks per week and cigarette use as pack-years. History of current or past cigarette use was also determined.

CEREBRAL MR IMAGES AND IMAGE ANALYSIS

The MR (1.5-T) imaging was performed at 4 study sites by means of a conventional spin-echo, double-echo sequence in the axial orientation with repetition time of 2000 milliseconds, echo time of 20/100 milliseconds, 24-cm field of view, and 5-mm contiguous slices from the vertex to the foramen magnum imaged in a 256 x 192 matrix and interpolated to 256 x 256 with 1 excitation. The MR imaging information was transferred to a central location for processing and analysis without knowledge of age, zygosity, and medical history of the subjects. Image evaluation was based on a semiautomated segmentation analysis that involves operator-guided removal of nonbrain elements as previously described.14, 27, 28, 29

The presence of cerebral infarction on MR imaging was determined from the size, location, and imaging characteristics of the lesion. Only lesions 3 mm or larger qualified for consideration as cerebral infarcts. Other necessary imaging characteristics included (1) cerebrospinal fluid density on the subtraction image and (2) if the cerebral infarct was in the basal ganglia area, distinct separation from the circle of Willis vessels.

Intrarater and interrater reliabilities for this method have been published.27, 29

APOLIPOPROTEIN E GENOTYPING

Since previous reports suggest that apolipoprotein E {epsilon}4 (ApoE4) is a risk factor for MCI and incipient AD,30, 31 ApoE genotype status categorized as a dichotomized variable (E4 present or absent) was included in this analysis. For ApoE structural locus genotyping, the polymerase chain reaction was used to amplify 244–base pair fragments that contain variant amino acid residues 112 (cystine -> arginine = {epsilon}4 allele) and 158 (arginine -> cystine = {epsilon}2 allele). Polymerase chain reaction products were then digested with the restriction enzyme HhaI and underwent electrophoresis on an 8% polyacrylamide nondenaturing gel.32 In this procedure, the most common {epsilon}3 allele is cut by HhaI at position 158; the {epsilon}4 allele is cut twice by the addition of a second restriction site at position 112; and the less frequent {epsilon}2 allele lacks either recognition site. Genotyping by using this technique was completed on 589 individual twins of this cohort, showing allele frequencies of {epsilon}2 = 0.09, {epsilon}3 = 0.76, and {epsilon}4 = 0.15, consistent with expected frequencies in other white populations.33 The ApoE genotypes were available on 359 (97%) of the individuals in the subset of 369 of NHLBI twins used in the present analysis.

DEFINITION OF MCI

Mild cognitive impairment is commonly defined as the presence of clinically significant memory impairment in the absence of a clinical dementia.22 Various measures of memory performance can be used.22 For the purpose of this analysis, we defined MCI on the basis of delayed free-recall performance on the California Verbal Learning Test (CVLT). The CVLT34 quantifies numerous components of verbal learning and memory and has demonstrated validity in persons with AD.35 While performance on the CVLT is affected by both age and sex,34 few normative studies have been performed on older individuals since its publication.36 Therefore, MCI was defined as a score of 4 or less, corresponding to the lower 10th percentile of the distribution of scores or 1.4 SDs below the mean, consistent with MCI as defined by other memory tests.22 In addition, to exclude the presence of frank dementia, subjects with a score of 24 or less on the Mini-Mental State Examination were excluded from the analysis (n = 45).

STATISTICAL ANALYSIS

To assess validity of designating MCI on the basis of performance within the NHLBI cohort, initial statistical analysis examined the distribution of scores from the long-term delayed recall portion of the CVLT by means of the SAS univariate procedure and the Kolomogorov D statistic.37 Between-group comparisons on a variety of demographic, genotypic, and cerebrovascular risk factors were performed by means of the t test. Forward stepwise logistic regression analysis was used to evaluate the relative risk and 95% confidence intervals for variables significantly associated with the presence of MCI. Because of missing ApoE data for 3% of the cohort, the number of subjects differed slightly between the univariate analysis, which included 369 individuals, and the logistic regression analyses, which included 359 individuals. All analyses were conducted with the SAS statistical package (version 6.09; SAS Institute Inc, Cary, NC). Data are given as mean ± SD unless otherwise indicated.


RESULTS
 Jump to Section
 •Top
 •Introduction
 •Subjects and methods
 •Results
 •Comment
 •Author information
 •References

The distribution of scores on CVLT delayed free recall are displayed in Figure 1. Since MCI was a priori defined as the lower 10th percentile or 1.4 SDs or more below the group mean, 37 subjects with a CVLT score of 4.0 or less were identified as having MCI. The average performance on the delayed free recall of the CVLT across all subjects was 8.18 ± 2.92. The mean performance for the MCI group was 2.97 ± 1.26, and for the normal memory group, 8.77 ± 2.44. Performance on CVLT delayed free recall across all subjects was very similar to that in other previously described elderly cohorts where individuals were between the ages of 64 and 77 years (mean, 8.18; SD, 2.82).36



View larger version (26K):
[in this window]
[in a new window]
Histogram distribution of delayed free-recall scores on the California Verbal Learning Test for all subjects participating in this study. The heights of the bars indicate the number of subjects at each value with that score. The arrow indicates the cutoff score used to determine the presence of mild cognitive impairment.


Between-group comparisons are summarized in Table 1. Subjects with MCI were significantly older (73.5 ± 3.0 years vs 72.1 ± 2.8 years), consumed significantly less alcohol (3.7 ± 5.8 drinks per week vs 7.0 ± 10.7 drinks per week), and had significantly greater WMHI volumes (0.56% ± 0.82% of cranial volume vs 0.25% ± 0.34% of cranial volume) than subjects with normal delayed free recall.


View this table:
[in this window]
[in a new window]
Table 1. Univariate Comparisons of Age, Education, CVD Risk Factors, Medical Histories, and Brain Volumes on MR Imaging in Subjects With and Without Mild Cognitive Impairment*


Results of stepwise logistic regression are summarized in Table 2. Since symptomatic stroke is associated with a significant increase in risk for dementia,38 we also examined significant risk factors for MCI for the entire subject group (model 1) and then repeated the analysis excluding subjects with a history of any symptomatic cerebrovascular disease (model 2). This excluded 6 subjects in the MCI group and 37 control subjects from the model 2 analysis. Age, WMHI, and the presence of the ApoE4 genotype were associated with a significantly increased risk of MCI in both analytical models. Relative risk was calculated for each year of age and percentage change in WMHI volume as a proportion of cranial volume (eg, subjects with 1% WMHI volume were 2.31 times more likely to have MCI than those with minimal volumes of WMHI). When all subjects were included in the analysis (model 1), alcohol consumption (risk calculated as drinks per day) was additionally associated with a significant risk reduction for MCI. When subjects with a history of symptomatic cerebrovascular disease were excluded from the analysis (model 2), diastolic BP at examination 1 (calculated as 1 SD of the mean or 12.5 mm Hg) was additionally associated with a significantly increased risk of MCI.


View this table:
[in this window]
[in a new window]
Table 2. Adjusted RR Ratios and 95% CIs From Stepwise Logistic Regression Analyses That Include (Model 1) and Exclude (Model 2) Subjects With Clinical CVA*



COMMENT
 Jump to Section
 •Top
 •Introduction
 •Subjects and methods
 •Results
 •Comment
 •Author information
 •References

Our results show that elevations in midlife diastolic BP and WMHI volumes are significant risk factors for MCI in a large group of community-dwelling older men. Moreover, the relative risk for MCI related to WMHI is at least as great as, if not greater than, the relative risk for MCI attributable to the presence of the ApoE4 genotype. Importantly, however, the pathophysiology of MCI caused by brain vascular disease is likely to differ substantially from that of the more common "neurodegenerative" type22, 23 that often progresses to AD. Since our data suggest that MCI is a heterogeneous condition, future work will be necessary to determine the actual likelihood that MCI of the "vascular" type might progress to clinical dementia and, if so, the type of dementia expressed (ie, AD vs vascular dementia).

In addition to identifying factors that increase the risk for MCI, we also found that alcohol consumption was slightly protective. This finding supports previous data showing a positive correlation between alcohol consumption and cognitive performance.39 This effect appeared significant only for individuals with cerebrovascular disease, as it was not present in model 2. How alcohol consumption might reduce the risk of later-life MCI is presently unclear.39 Recent evidence suggests that moderate alcohol consumption can reduce the risk of both vascular disease and AD.40, 41 Unfortunately, the current study was not designed to test potential causes of MCI risk reduction due to alcohol consumption, and further research in this area is clearly necessary. Fortunately, another clinical evaluation of this group is ongoing. Assessing dementia incidence and type of dementia in this cohort may give some clues to the protective effect of alcohol consumption for these individuals.

We have previously shown that midlife diastolic BP is a significant predictor of later-life WMHI volume.14 We also have shown that extensive WMHI volumes are significantly associated with an increased rate of decline on measures of attention, memory, and verbal fluency.15 We believe these cognitive changes result from the effect of elevated BP on the brain.15 Unfortunately, the magnitude of cognitive impairment related to WMHI noted in previous studies has been relatively small.6, 9, 13, 18, 19, 20, 21 The results of this study suggest that the impact of elevated BP and increased WMHI may be clinically relevant in that they both increase the risk of MCI in subjects without a history of symptomatic cerebrovascular disease.

Our data also confirm that MCI is likely to be a pathologically heterogeneous disorder. Previous studies suggest that MCI is part of the continuum that ranges from healthy aging to AD.22 The ApoE4 genotype increases both the lifetime risk of AD42 and the risk of conversion of MCI to AD,30 presumably through enhanced amyloid deposition43 or increased neuronal vulnerability.44 Our finding that ApoE4 genotype status independently increased subject risk for MCI is consistent with these previously published reports. The fact that both ApoE4 genotype status and WMHI volume independently increased risk of MCI suggests the possibility of 2 independent processes leading to MCI, supporting the notion of MCI as a pathologically as well as clinically heterogeneous disorder.22 Importantly, there are no data yet available regarding the potential impact of WMHI volume on the progression from MCI to clinically probable AD or other dementia. Current ongoing work with the subjects of the NHLBI Twin Study may allow us to directly examine the relationship between WMHI volume, current MCI status, and dementia incidence.

It is likely that vascular risk factors, such as hypertension, cause MCI through mechanisms different from AD. Chronic essential hypertension is associated with age-related differences in brain structure and function,7, 9, 10, 11, 12, 13, 14 which in the presence of WMHI are associated with cognitive impairment.9, 13, 15, 18, 19, 20, 21 We have previously shown that extensive amounts of WMHI are associated with reduced cerebral metabolism of glucose in the frontal lobes of otherwise healthy individuals.6 This may reflect preferential impairment of frontal-subcortical circuits by WMHI.45, 46 While frontal-subcortical circuits generally are not considered involved with memory encoding, they may underlie working memory function.47, 48 It is possible that the CVLT is a type of task that uses these frontal circuits.49 Alternatively, recent evidence suggests that cerebrovascular disease may interact significantly with pathologic changes of AD to enhance the expression of clinical dementia.50 It is possible that a similar phenomenon could occur with WMHI. Future work in this area of research may help to define the potential interaction between these 2 very common age-related diseases.

Two important limitations to this study also should be mentioned. For all these analyses, twin subjects were treated as individuals. First, although we found no evidence that the twin condition affected our results, all of the monozygotic twins and many of the dizygotic twins share ApoE4 genotype. The WMHI volumes are also highly heritable.51 Second, the NHLBI cohort is exclusively male and mostly white. These sex and ethnic restrictions further reduce our ability to generalize these findings. However, there is important evidence that WMHI volumes are increased in women and African Americans,9, 12 suggesting that the impact of WMHI on MCI may be greater than that observed with this cohort. Replication of these findings in a more representative population, therefore, will be important to understanding the full significance of these observations.

Finally, these observations may have therapeutic implications. If midlife elevations of diastolic BP lead to later-life MCI and potentially cause WMHI,14 then greater awareness and treatment of midlife BP elevations may lower the risk of later-life MCI. Our finding that the effect of midlife diastolic BP and WMHI volumes on later-life cognition is at least as great as that of ApoE4 genotype also suggests that the clinical impact of this risk reduction could be considerable. Further research into the issues of midlife BP control as it relates to later-life cognitive function is clearly needed.


AUTHOR INFORMATION
 Jump to Section
 •Top
 •Introduction
 •Subjects and methods
 •Results
 •Comment
 •Author information
 •References

Accepted for publication July 11, 2000.

This work was supported by grant HL51429 from the National Heart, Lung, and Blood Institute, Bethesda, Md.

From the Department of Neurology, University of Kansas, Kansas City (Dr DeCarli); Department of Neurology, University of California at San Francisco (Dr Miller); Health Sciences Division, SRI International, Menlo Park, Calif (Drs Swan and Carmelli); Department of Medical and Molecular Genetics, Indiana University, Indianapolis (Dr Reed); and Department of Neurology, Boston University, Boston, Mass (Dr Wolf). Dr DeCarli is now with the Department of Neurology, University of California at Davis.

Corresponding author and reprints: Charles DeCarli, MD, Department of Neurology, University of California at Davis, 4860 Y St, Suite 3700, Sacramento, CA 95817 (e-mail: cdecarli{at}ucdavis.edu).


REFERENCES
 Jump to Section
 •Top
 •Introduction
 •Subjects and methods
 •Results
 •Comment
 •Author information
 •References

1. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138:353-364. FREE FULL TEXT
2. Elias PK, D'Agostino RB, Elias MR, Wolf PA. Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Exp Aging Res. 1995;21:393-417. ISI | PUBMED
3. Elias MF, D'Agostino RB, Elias PK, Wolf PA. Neuropsychological test performance, cognitive functioning, blood pressure, and age: the Framingham Heart Study. Exp Aging Res. 1995;21:369-391. ISI | PUBMED
4. Launer LJ, Masaki K, Petrovich H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851. FREE FULL TEXT
5. Swan GE, Carmelli D, LaRue A. Relationship between blood pressure during middle age and cognitive impairment in old age: the Western Collaborative Group Study. Aging Neuropsychol Cogn. 1996;3:241-250. FULL TEXT
6. DeCarli C, Murphy DGM, Tran M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance and cerebral metabolism in 51 healthy adults. Neurology. 1995;45:2077-2084. FREE FULL TEXT
7. Mentis MJ, Salerno J, Horwitz B, et al. Reduction of functional neuronal connectivity in long-term treated hypertension. Stroke. 1994;25:601-607. ABSTRACT
8. Herholz K, Heindel W, Rackl A, et al. Regional cerebral blood flow in patients with leuko-araiosis and atherosclerotic carotid artery disease. Arch Neurol. 1990;47:392-396. FREE FULL TEXT
9. Longstreth WT, Manolio TA, Arnold A, et al for the Cardiovascular Health Study. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. Stroke. 1996;27:1274-1282. FREE FULL TEXT
10. Salerno JA, Murphy DGM, Horwitz B, et al. Brain atrophy in older hypertensive men: a volumetric magnetic resonance study. Hypertension. 1992;20:340-348. FREE FULL TEXT
11. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults: the Cardiovascular Health Study. Stroke. 1994;25:318-327. ABSTRACT
12. Liao D, Cooper L, Cai J, et al for the ARIC Study. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. Stroke. 1996;27:2262-2270. FREE FULL TEXT
13. van Sweiten JC, Geyskes CG, Derix MA, et al. Hypertension in the elderly is associated with white matter lesions and cognitive decline. Ann Neurol. 1991;30:825-830. FULL TEXT | ISI | PUBMED
14. DeCarli C, Miller BL, Swan GE, et al. Predictors of brain morphology for the men of the NHLBI Twin Study. Stroke. 1999;30:529-536. FREE FULL TEXT
15. Swan GE, DeCarli C, Miller BL, et al. The association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology. 1998;51:986-993. FREE FULL TEXT
16. Strassburger TL, Lee HC, Daly E, et al. Interactive effects of age and hypertension on volumes of brain structures. Stroke. 1997;28:1410-1417. FREE FULL TEXT
17. O'Brien JT, Desmond P, Ames D, Schweitzer I, Tress B. Magnetic resonance imaging correlates of memory impairment in the healthy elderly: association with medial temporal lobe atrophy but not white matter lesions. Int J Geriatr Psychiatry. 1997;12:369-374. FULL TEXT | ISI | PUBMED
18. Schmidt R, Fazekas F, Koch M, et al. Magnetic resonance imaging, cerebral abnormalities and neuropsychological test performance in elderly hypertensive subjects: a case-control study. Arch Neurol. 1995;52:905-910. FREE FULL TEXT
19. Baum KA, Schulte C, Girke W, Reischies FM, Felix R. Incidental white-matter foci on MRI in "healthy" subjects: evidence of subtle cognitive dysfunction. Neuroradiology. 1996;38:755-760. FULL TEXT | ISI | PUBMED
20. Kasahara H, Yamada H, Tanno M, et al. Magnetic resonance imaging study of the brain in aged volunteers: T2 high intensity lesions and higher order cortical function. Psychiatry Clin Neurosci. 1995;49:273-279. PUBMED
21. Boone KB, Miller BL, Lesser IM, et al. Neuropsychological correlates of white-matter lesions in healthy elderly subjects: a threshold effect. Arch Neurol. 1992;49:549-554. FREE FULL TEXT
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tanglaols EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308. FREE FULL TEXT
23. Dawe B, Procter A, Philpot M. Concepts of mild cognitive impairment in the elderly and their relationship to dementia: a review. Int J Geriatr Psychiatry. 1992;7:473-479.
24. Jablon S, Neel JV, Gershowitz H, Atkinson GF. The NAS-NRC twin panel: methods of construction of the panel, zygosity diagnosis and proposed use. Am J Hum Genet. 1967;19:133-161. ISI | PUBMED
25. Feinleib M, Garrison RJ, Fabsitz RR, et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. Am J Epidemiol. 1977;106:284-295. FREE FULL TEXT
26. Reed T, Quiroga J, Selby JV, et al. Concordance of ischemic heart disease in the NHLBI Twin Study after 14-18 years of follow-up. J Clin Epidemiol. 1991;44:797-805. FULL TEXT | ISI | PUBMED
27. DeCarli C, Maisog J, Murphy DGM, Teichberg D, Rapoport SI, Horwitz B. Method for quantification of brain, central and subarachnoid CSF volumes from magnetic resonance images. J Comput Assist Tomogr. 1992;16:274-284. ISI | PUBMED
28. DeCarli C, Murphy DGM, Teichberg D, Campbell G, Sobering GS. Local histogram correction of MRI spatially dependent image pixel intensity nonuniformity. J Magn Reson Imaging. 1996;6:519-528. ISI | PUBMED
29. Murphy DGM, DeCarli C, Schapiro MB, Rapoport SI, Horwitz B. Age-related differences in volumes of subcortical nuclei, brain matter, and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. Arch Neurol. 1992;49:839-845. FREE FULL TEXT
30. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278. FREE FULL TEXT
31. Petersen RC, Waring SC, Smith GE, Tangalos EG, Thibodeau SN. Predictive value of APOE genotyping in incipient Alzheimer's disease. Ann N Y Acad Sci. 1996;802:58-69. ISI | PUBMED
32. Hixon JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res. 1990;3:545-548.
33. Schachter F, Faure-Delanef L, Guenot F, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet. 1994;6:29-32. FULL TEXT | ISI | PUBMED
34. Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test. New York, NY: Psychological Corp; 1987.
35. Bondi MW, Monsch AU, Galask D, Butters N, Salmon DP, Delis DC. Preclinical cognitive markers of dementia of the Alzheimer's type. Neuropsychology. 1994;8:374-384. FULL TEXT
36. Paolo AM, Tröster AI, Ryan JJ. California Verbal Learning Test: normative data for the elderly. J Clin Exp Neuropsychol. 1997;19:220-234. ISI | PUBMED
37. Stephens MA. EDF statistics for goodness of fit and some comparisons. J Am Stat Assoc. 1974;69:730-737. FULL TEXT | ISI
38. Tatemichi TK, Bagiella E, Desmond DW, et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology. 1994;44:1885-1891. FREE FULL TEXT
39. Elias PK, Elias MF, D'Agostino RB, Silbershatz H, Wolf PA. Alcohol consumption and cognitive performance in the Framingham Heart Study. Am J Epidemiol. 1999;150:580-589. FREE FULL TEXT
40. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med. 1988;319:267-273. ABSTRACT
41. Orogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol Paris. 1997;153:185-192. PUBMED
42. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92:4725-4727. FREE FULL TEXT
43. McNamara MJ, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype and deposits of Aß40 and Aß42 in Alzheimer disease. Arch Neurol. 1998;55:1001-1004. FREE FULL TEXT
44. Chen Y, Lomnitski L, Michaelson DM, Shohami E. Motor and cognitive deficits in apolipoprotein e–deficient mice after closed head injury. Neuroscience. 1997;80:1255-1262. FULL TEXT | ISI | PUBMED
45. Pantoni L, Garcia JH. Cognitive impairment and cellular/vascular changes in the cerebral white mater. Ann N Y Acad Sci. 1997;826:92-102. Review. ISI | PUBMED
46. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994;6:358-370. FREE FULL TEXT
47. Tulving E, Markowitsch HJ. Memory beyond the hippocampus. Curr Opin Neurobiol. 1997;7:209-216. FULL TEXT | ISI | PUBMED
48. Nyberg L, McIntosh AR, Cabeza R, Habib R, Houle S, Tulving E. General and specific brain regions involved in encoding and retrieval of events: what, where, and when. Proc Natl Acad Sci U S A. 1996;93:11280-11285. FREE FULL TEXT
49. Cabeza R, Grady CL, Nyberg L, et al. Age-related differences in neural activity during memory encoding and retrieval: a positron emission tomography study. J Neurosci. 1997;17:391-400. FREE FULL TEXT
50. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277:813-817. FREE FULL TEXT
51. Carmelli D, DeCarli C, Swan GE, et al. Genetic variability of white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177-1181. FREE FULL TEXT


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2001;58(4):684-685.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Regional pattern of white matter microstructural changes in normal aging, MCI, and AD
Lee et al.
Neurology 2009;73:1722-1728.
ABSTRACT | FULL TEXT  

Differences in Brain Volume, Hippocampal Volume, Cerebrovascular Risk Factors, and Apolipoprotein E4 Among Mild Cognitive Impairment Subtypes
He et al.
Arch Neurol 2009;66:1393-1399.
ABSTRACT | FULL TEXT  

Subclinical cerebrovascular disease in mild cognitive impairment
Luchsinger et al.
Neurology 2009;73:450-456.
ABSTRACT | FULL TEXT  

Mediterranean Diet and Mild Cognitive Impairment
Scarmeas et al.
Arch Neurol 2009;66:216-225.
ABSTRACT | FULL TEXT  

Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes
Kantarci et al.
Arch Neurol 2008;65:1621-1628.
ABSTRACT | FULL TEXT  

The Apolipoprotein E {epsilon}4 Allele is not Associated With Cognitive Dysfunction in Cardiac Surgery
Silbert et al.
Ann. Thorac. Surg. 2008;86:841-847.
ABSTRACT | FULL TEXT  

Association of Blood Pressure and Genetic Background With White Matter Lesions in Patients With Mild Cognitive Impairment
Galluzzi et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2008;63:510-517.
ABSTRACT | FULL TEXT  

Spatial Distribution of White-Matter Hyperintensities in Alzheimer Disease, Cerebral Amyloid Angiopathy, and Healthy Aging
Holland et al.
Stroke 2008;39:1127-1133.
ABSTRACT | FULL TEXT  

Magnetic Resonance Imaging White Matter Hyperintensities and Brain Volume in the Prediction of Mild Cognitive Impairment and Dementia
Smith et al.
Arch Neurol 2008;65:94-100.
ABSTRACT | FULL TEXT  

Prevalence of Subcortical Vascular Lesions and Association With Executive Function in Mild Cognitive Impairment Subtypes
Bombois et al.
Stroke 2007;38:2595-2597.
ABSTRACT | FULL TEXT  

Endothelial Function and White Matter Hyperintensities in Older Adults With Cardiovascular Disease
Hoth et al.
Stroke 2007;38:308-312.
ABSTRACT | FULL TEXT  

Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD
Yoshita et al.
Neurology 2006;67:2192-2198.
ABSTRACT | FULL TEXT  

Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease
Portet et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:714-718.
ABSTRACT | FULL TEXT  

Clinical trials in mild cognitive impairment: lessons for the future
Jelic et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:429-438.
ABSTRACT | FULL TEXT  

Association of White Matter Hyperintensity Volume With Decreased Cognitive Functioning: The Framingham Heart Study
Au et al.
Arch Neurol 2006;63:246-250.
ABSTRACT | FULL TEXT  

Decline in intelligence is associated with progression in white matter hyperintensity volume
Garde et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:1289-1291.
ABSTRACT | FULL TEXT  

Anatomical Mapping of White Matter Hyperintensities (WMH): Exploring the Relationships Between Periventricular WMH, Deep WMH, and Total WMH Burden
DeCarli et al.
Stroke 2005;36:50-55.
ABSTRACT | FULL TEXT  

MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET
Mosconi et al.
Neurology 2004;63:2332-2340.
ABSTRACT | FULL TEXT  

Vascular risk factors, incidence of MCI, and rates of progression to dementia
Solfrizzi et al.
Neurology 2004;63:1882-1891.
ABSTRACT | FULL TEXT  

Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia
DeCarli et al.
Neurology 2004;63:220-227.
ABSTRACT | FULL TEXT  

Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment
Korf et al.
Neurology 2004;63:94-100.
ABSTRACT | FULL TEXT  

Cerebrospinal Fluid Tau Protein and Periventricular White Matter Lesions in Patients With Mild Cognitive Impairment: Implications for 2 Major Pathways
Maruyama et al.
Arch Neurol 2004;61:716-720.
ABSTRACT | FULL TEXT  

Framingham Stroke Risk Profile and Lowered Cognitive Performance
Elias et al.
Stroke 2004;35:404-409.
ABSTRACT | FULL TEXT  

Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC
Frisoni et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:1371-1381.
ABSTRACT | FULL TEXT  

Blood Pressure and Cognitive Impairment in India and the United States: A Cross-National Epidemiological Study
Pandav et al.
Arch Neurol 2003;60:1123-1128.
ABSTRACT | FULL TEXT  

Cigarette Smoking and Alcohol Consumption in Relation to Cognitive Performance in Middle Age
Kalmijn et al.
Am J Epidemiol 2002;156:936-944.
ABSTRACT | FULL TEXT  

Cognitive decline in AD and mild cognitive impairment is associated with global brain damage
van der Flier et al.
Neurology 2002;59:874-879.
ABSTRACT | FULL TEXT  

Alzheimer Disease as a Vascular Disorder: Nosological Evidence
de la Torre
Stroke 2002;33:1152-1162.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.